慢性髓性白血病酪氨酸激酶抑制剂停药研究(EURO-SKI)预设中期分析
EURO-SKI是一项前瞻性、多中心、非随机试验,纳入758例慢性期慢性髓性白血病患者,旨在明确停用酪氨酸激酶抑制剂的条件。预设中期分析显示,可评估的755例患者6个月无分子学复发生存率为61%,24个月为50%。结论认为获得深度分子学反应的患者可考虑停药,尤其深度分子学反应持续时间较长者。
要点
- 获得深度分子学反应的患者停用TKI后6个月无分子学复发生存率为61%。
- 停药后24个月无分子学复发生存率为50%。
- 较长治疗时间和较长深度分子学反应持续时间与6个月维持MMR概率增加相关。
核心结论
- 获得深度分子学反应的慢性髓性白血病患者停用TKI后无分子学复发生存良好,可考虑停药。
研究设计与样本
- 前瞻性、多中心、非随机试验,在11个国家61个欧洲中心纳入758例慢性期慢性髓性白血病患者。
- 患者须接受任何TKI至少3年且无治疗失败,并确认深度分子学反应至少1年。
- 预设中期分析在200例患者6个月无分子学复发生存状态已知后进行;研究注册号NCT01596114。
主要发现
- 755例可评估分子学反应的患者中位随访27个月(IQR 21-34)。
- 6个月无分子学复发生存率为61%(95%CI 57-64),24个月为50%(95%CI 46-54)。
- 755例中371例(49%)停药后失去MMR,4例(1%)在MMR期间死于与慢性髓性白血病无关的原因。
- 13例(2%)在MMR期间重新开始TKI治疗,6例(1%)失去MMR并重新TKI治疗后死于无关原因,2例(<1%)重新TKI治疗后仍失去MMR。
关键数值与推荐
- 停药条件:慢性期慢性髓性白血病,接受任何TKI至少3年且无治疗失败,确认深度分子学反应至少1年。
临床怎么用
- 获得深度分子学反应且持续时间较长的慢性髓性白血病患者可考虑停用TKI。
- 停药可避免治疗相关副作用并减少医疗支出。
局限性
- 本次报告为预设中期分析,研究仍在进行中。
- 研究为非随机设计。
- 验证样本中深度分子学反应持续时间的关联未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define precise conditions for stopping treatment. METHODS: In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. The primary endpoint was molecular relapse-free survival, defined by loss of major molecular response (MMR; >0·1% BCR-ABL1 on the International Scale) and assessed in all patients with at least one molecular result. Secondary endpoints were a prognostic analysis of factors affecting maintenance of MMR at 6 months in learning and validation samples and the cost impact of stopping TKI therapy. We considered loss of haematological response, progress to accelerated-phase chronic myeloid leukaemia, or blast crisis as serious adverse events. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. The study is ongoing and is registered with ClinicalTrials.gov, number NCT01596114. FINDINGS: Between May 30, 2012, and Dec 3, 2014, we assessed 868 patients with chronic myeloid leukaemia for eligibility, of whom 758 were enrolled. Median follow-up of the 755 patients evaluable for molecular response was 27 months (IQR 21-34). Molecular relapse-free survival for these patients was 61% (95% CI 57-64) at 6 months and 50% (46-54) at 24 months. Of these 755 patients, 371 (49%) lost MMR after TKI discontinuation, four (1%) died while in MMR for reasons unrelated to chronic myeloid leukaemia (myocardial infarction, lung cancer, renal cancer, and heart failure), and 13 (2%) restarted TKI therapy while in MMR. A further six (1%) patients died in chronic-phase chronic myeloid leukaemia after loss of MMR and re-initiation of TKI therapy for reasons unrelated to chronic myeloid leukaemia, and two (<1%) patients lost MMR despite restarting TKI therapy. In the prognostic analysis in 405 patients who received imatinib as first-line treatment (learning sample), longer treatment duration (odds ratio [OR] per year 1·14 [95% CI 1·05-1·23]; p=0·0010) and longer deep molecular response durations (1·13 [1·04-1·23]; p=0·0032) were associated with increasing probability of MMR maintenance at 6 months. The OR for deep molecular response duration was replicated in the validation sample consisting of 171 patients treated with any TKI as first-line treatment, although the association was not significant (1·13 [0·98-1·29]; p=0·08). TKI discontinuation was associated with substantial cost savings (an estimated €22 million). No serious adverse events were reported. INTERPRETATION: Patients with chronic myeloid leukaemia who have achieved deep molecular responses have good molecular relapse-free survival. Such patients should be considered for TKI discontinuation, particularly those who have been in deep molecular response for a long time. Stopping treatment could spare patients from treatment-induced side-effects and reduce health expenditure. FUNDING: ELN Foundation and France National Cancer Institute.
引用
- Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018. PMID: 29735299. doi:10.1016/S1470-2045(18)30192-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。